Cue Biopharma, Inc. financial data

Symbol
CUE on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 153% % -38%
Debt-to-equity 129% % 66%
Return On Equity -272% % -74%
Return On Assets -119% % -35%
Operating Margin -538% % -12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78,737,736 shares 24%
Common Stock, Shares, Outstanding 77,781,743 shares 29%
Entity Public Float $59,900,000 USD -61%
Common Stock, Value, Issued $78,000 USD 30%
Weighted Average Number of Shares Outstanding, Basic 100,869,349 shares 97%
Weighted Average Number of Shares Outstanding, Diluted 100,869,349 shares 97%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $7,100,000 USD -26%
Research and Development Expense $28,396,000 USD -29%
General and Administrative Expense $16,812,000 USD 11%
Operating Income (Loss) $38,163,000 USD 16%
Nonoperating Income (Expense) $480,000 USD -56%
Net Income (Loss) Attributable to Parent $37,683,000 USD 16%
Earnings Per Share, Basic 0 USD/shares 53%
Earnings Per Share, Diluted 0 USD/shares 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $11,701,000 USD -64%
Accounts Receivable, after Allowance for Credit Loss, Current $387,000 USD -88%
Assets, Current $25,819,000 USD -31%
Property, Plant and Equipment, Net $307,000 USD -46%
Operating Lease, Right-of-Use Asset $4,602,000 USD 14%
Other Assets, Noncurrent $96,000 USD -11%
Assets $31,644,000 USD -29%
Accounts Payable, Current $2,348,000 USD -64%
Accrued Liabilities, Current $1,871,000 USD -42%
Liabilities, Current $15,524,000 USD -7.5%
Operating Lease, Liability, Noncurrent $2,684,000 USD 102%
Liabilities $18,398,000 USD -5.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,000 USD
Retained Earnings (Accumulated Deficit) $370,051,000 USD -11%
Stockholders' Equity Attributable to Parent $13,246,000 USD -48%
Liabilities and Equity $31,644,000 USD -29%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,172,000 USD 16%
Net Cash Provided by (Used in) Financing Activities $1,000,000 USD -142%
Net Cash Provided by (Used in) Investing Activities $150,000 USD -173%
Common Stock, Shares Authorized 300,000,000 shares 200%
Common Stock, Shares, Issued 77,781,743 shares 29%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,322,000 USD -25%
Interest Paid, Excluding Capitalized Interest, Operating Activities $90,000 USD -57%
Deferred Tax Assets, Valuation Allowance $93,965,000 USD 12%
Deferred Tax Assets, Gross $95,178,000 USD 11%
Operating Lease, Liability $4,715,000 USD 12%
Depreciation $362,000 USD -22%
Payments to Acquire Property, Plant, and Equipment $150,000 USD 173%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $37,682,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid $5,301,000 USD 20%
Property, Plant and Equipment, Gross $3,904,000 USD -13%
Operating Lease, Liability, Current $2,031,000 USD -30%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,228,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year One $630,000 USD -22%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 67%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $586,000 USD 194%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,884,000 USD 130%
Deferred Tax Assets, Operating Loss Carryforwards $58,121,000 USD 8.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,138,000 USD 7.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four $559,000 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,213,000 USD -32%
Share-based Payment Arrangement, Expense $5,696,000 USD -23%
Interest Expense $100,000 USD -15%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%